関連する実験動画
Updated: May 11, 2026
13:42
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
閉塞性心不全の患者における補足剤の活性化:高用量静脈注射免疫グロブリン治療の効果
P Aukrust1, L Gullestad, K T Lappegård
1Section of Clinical Immunology and Infectious Diseases, Research Institute for Internal Medicine, Rikshospitalet, University of Oslo, Norway. pal.aukrust@rikshospitalet.no
Circulation
|September 26, 2001
まとめ
閉塞性心不全 (CHF) は先天的な免疫を伴うもので,CHFの患者では,特に冠動脈循環において,補完体の活性化が増加する. IVIG療法により,補完体の活性化が強化され,改善された心臓機能と負の相関関係がありました.
科学分野:
- 免疫学 免疫学とは
- 心臓病学 心臓病学
- 生まれながらの免疫力
背景:
- 閉塞性心不全 (CHF) の病原性は,生まれつきの免疫とますます結びついている.
- CHFにおいて,重要な先天性免疫の構成要素であるコンプリメント・システムの特定の役割を調査しています.
研究 の 目的:
- CHF患者の全身循環と冠動脈循環における補完体の活性化を分析する.
- IVIGの左心室放出分数 (LVEF) に対する治療効果が,補完体調節に関連しているかどうかを判断する.
主な方法:
- 系統的および冠動脈動脈の血液における補完体活性化経路 (古典的,代替的,末端的) を分析した.
- 39人の心筋梗塞患者と20人の健康な対照群のコンプリメント活性化を比較した.
- ダブルブラインド,プラセボ対照試験でIVIGまたはプラセボ療法中に補足剤の活性化を評価しました.
主要な成果:
- CHFの患者は,対照群と比較して,全身的および冠動脈補完体の活性化が強化されたことを示した.
- IVIG療法,特に誘導時のIVIG療法では,全身的な補完体の活性化が著しく増加しました.
- IVIG媒介の補足剤活性化の増加は,LVEFの改善と負の相関を示した.
結論:
- 発見は,CHFの病原性における先天性免疫,特に補足の役割を支持しています.
- コンプリメントは,CHFの潜在的な治療目標です.
- CHFに対するコンプレメント阻害剤に関するさらなる研究が必要である.
関連する概念動画
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...